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Combination therapy with mexiletine and quinidine has
been shown to be more effective than either agent alone.
The ability of mexiletine monotherapy, quinidine mono-
therapy and mexiletine-quinidine combination therapy
to suppress inducible sustained ventricular tachycardia
was related to drug-induced changes in ventricular re-
fractoriness, conduction times and monophasic action
potential duration recorded from both ventricles. Ven-
tricular tachycardia could no longer be induced in 7
(35%) of the 20 patients studied with combination ther-
apy. This was a significantly higher proportion of pa-
tients than that of the groups responding to either
monotherapy (quinidine, 10%; mexiletine, 5%).
Ventricular effective and functional refractory pe-
riods were measured when applying single (8 2) , double
(8.1) and triple (S4) extrastimuli. Quinidine monotherapy
increased functional and effective refractory periods of
both single and multiple extrastimuli. However, when
comparing measurements made during mexiletine treat-
ment with those at baseline, mexiletine monotherapy
increased only the refractory periods of S4' The effective
Combination therapy with mexiletine and quinidine has been
shown to be more effective than therapy with either agent
alone for the suppression of spontaneous ventricular tachy-
cardia (1,2). The combination of a class Ia and class Ib
antiarrhythmic agent has also been reported (3) to suppress
inducible sustained ventricular tachycardia. The electro-
physiologic correlates of this interaction have not been sys-
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refractory period of 84 during mexiletine monotherapy
(200 ± 20 ms) was significantly longer than at baseline
(160 ± 21 ms). Similarly, when comparing measure-
ments made during combination therapy with those dur-
ing quinidine monotherapy, combination therapy sig-
nificantly increased the refractory periods only of multiple
extrastimuli. The effective refractory period of 84during
combination therapy (253 ± 26 ms) was significantly
longer than that of quinidine monotherapy (223 ± 27
ms). The only other significant difference between com-
bination therapy and monotherapy with either agent was
a greater prolongation of conduction time to the left
ventricular dyskinetic zone with combination therapy.
Therefore, mexiletine-quinidine combination therapy
is associated with additional prolongation of the refrac-
tory periods of multiple extrastimuli and with further
prolongation of conduction into the dyskinetic zone of
the left ventricle. These electrophysiologic effects may
be markers of enhanced antiarrhythmic activity.
(1 Am Coil Cardiol 1987;10:1149-56)
tematically evaluated in humans. Accordingly, we assessed
the relative antiarrhythmic efficacy of mexiletine, quinidine
and their combination in the suppression of inducible. sus-
tained ventricular tachycardia. Antiarrhythmic activity was
related to drug-induced changes in ventricular refractori-
ness, conduction times and monophasic action potential du-
rations recorded from the right ventricle and from an area
of the left ventricle with a segmental wall motion abnor-
mality.
Methods
Study patients. Patients referred for treatment of symp-
tomatic ventricular tachycardia or syncope of obscure origin
were potential candidates for this study. After withdrawal
of all antiarrhythmic medications for at least 4 half-lives. a
trans venous catheter eIectrophysiologic study was per-
formed. If sustained unimorphic ventricular tachycardia was
0735·\O'l7/X7/S:1.50
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induced, the patient remained a candidate for this study.
Serial electrophysiologic testing with intravenous quinidine,
disopyrarnide, procainamide and propranolol wasperformed
unless treatment with one or more of these agents was con-
traindicated. When these agents were ineffective, the final
criterion for entry into this study was met. All patients gave
written informed consent, and this protocol was approved
by the local Institutional Review Board.
Of the 20 patients admitted to this study, 19 had athero-
sclerotic heart disease and I had arrhythmogenic right ven-
tricular dysplasia (Table I). Seventeen patients presented
withdocumentedsymptomatic ventriculartachyarrhythmias
(ventricular tachycardia in 15; ventricular fibrillation in 2)
and 3 had syncopeof obscureorigin with induciblesustained
monomorphic ventricular tachycardia. Sustained uni-
morphic ventricular tachycardia was induced in the two
individuals who had presented with ventricular fibrillation
during out-of-hospital cardiac arrest. There were 15 men
and 5 women, with a mean age of 54 ± 13 years. Their
global left ventricular ejection fraction, assessed by nuclear
angiography, was 35 ± 13%.
Study design. Oral therapy with mexiletine, quinidine
or their combination was instituted in a randomized se-
quence. For each drug, the dose was gradually increased to
the maximum well tolerated level. The dose of each agent
tested in combination was the same as that of each drug
testedas monotherapy. Whena treatmentregimenprevented
induction of ventricular tachycardia, that patient's partici-
pation was terminatedand the remaining therapies were not
evaluated.
Left ventricular function. Global left ventricular func-
tion and the presence of a segmental left ventricular wall
motion abnormality were documented by angiography. Global
left ventricular function was also assessed by radionuclide
angiography during an antiarrhythmic drug-free state, and
was followed serially during therapy with each agent alone
and in combination.
Electrophysiologic studies. Programmed electrical
stimulation techniques in this study involved the introduc-
tion of up to three right ventricular extrastimuli (10 times
late-diastolic pacing threshold; 2 ms pulse width) during
ventricularpacing at cycle lengths of 600, 500 and 400 ms.
S I, Sz, S3 and S4 represent the stimulus artifacts of the last
beat of the ventricular drive train, the first extrastimulus,
the second extrastimulus and the third extrastimulus, re-
spectively. Corresponding ventricular electrograms were
designated VI. v.. V3 and V4. The ventricular effective
refractoryperiod of the firstextrastimulus(Sz) was the long-
est S,Sz interval at which Sz failed to capture. The ventric-
ular functional refractory period of the first extrastimulus
(Sz) was the minimal V,Vz coupling interval during deter-
mination of the ventricular refractory curve. After deter-
mination of the ventricular effective and functional refrac-
tory periods of Sz; the first extrastimuluswas introduced 10
Table 1. Patient Demographics
Patient Age (yr) Drug Ejection Fraction
No. & Sex Presentation Resistance Diagnosis (%)
I 43M YF p.q CAD 12
2 67F Syncope p.q CAD 50
3 52M YT sustained p.q CAD 18
4 74M YT sustained p,q CAD 33
5 54M YT nonsustained p.d.q.pr CAD 24
6 30M YT sustained p.d.q.pr CAD 30
7 37F YT nonsustained p.d.q.pr CAD 43
8 74M YT sustained p,q CAD 33
9 55M Syncope p.d.q.pr CAD 38
to 60F Syncope p.d.q.pr CAD 43
II 46F YT nonsustained p.d.q.pr CAD 38
12 59M YT sustained p.d.q.pr CAD 25
13 50M Syncope YT p.d.q.pr CAD 32
nonsustained
14 67M YT sustained p.d.q.pr CAD 40
15 64F Syncope YT p.d.q.pr CAD 34
nonsustained
16 54M YF p.d.q.pr CAD 34
17 52M YT sustained p.d.q.pr CAD 43
18 28M YT sustained p.d.q.pr RYdys 65
19 69M YT sustained p.d.q.pr CAD 20
20 57M YT nonsustained p.d.q.pr CAD 50
CAD = coronary artery disease; d = disopyramide; F = female; M = male; p = procainamide; pr =
propranolol; q = quinidine; RYdys = right ventricular dysplasia; YF = ventricular fibrillation; YT = ven-
tricular tachycardia.
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ms above the ventricular effective refractory period of S ~ .
The second extrastimulus (S,) was then introduced, and its
coupling interval (S2S,) was progressively shortened. After
the determination of ventricular effective and functional re-
fractory periods of So, the second extrastimulus (SI) was
placed 10 ms above the ventricular effective refractory pe-
riod of S3' and the third extrastimulus (S-1) was then intro-
duced and its coupling interval (S3S-l) progressively short-
ened until failure to capture. When sustained ventricular
tachycardia was not induced with ventricular cxtrastimu-
lation, ventricular burst pacing (4 and 12 stimuli) at cycle
lengths from 300 to 240 ms in steps of 10 ms was applied.
Sustained ventricular tachycardia \\'a.\' defined as a non-
stimulated ventricular rhythm with a cycle length of less
than 500 ms that lasted 30 seconds or produced hemody-
namic compromise requiring immediate termination by tran-
sthoracic cardioversion or ventricular pacing. A complete
antiarrhythmic response was defined as failure of the in-
duction protocol to produce five or more nonstimulated con-
secutive ventricular depolarizations. A partial antiarrhyth-
mic response was defined as the induction of ventricular
tachycardia with three extrustimuli when only one or two
extrastimuli had been sufficient to induced sustained ven-
tricular tachycardia at baseline.
The follo wing electrophvsiologic variables lI 'e/"{' re-
corded at baseline and during drug treatments: PRoQRS.
QT and RR intervals. The rate-corrected QT (QTc) interval
was calculated from the formula: QTc = QT\/RR . If ven-
tricular tachycardia was inducible, its cycle length was mea-
sured.
Monophasic action potential recordings. Ventricular
monophasic action potential recordings were obtained using
bipolar endocardial suction electrode techniques developed
by Olsson et al. (4). Simultaneous recordings were obtained
from the right interventricular septum and from the previ-
ously defined area of wall motion abnormality in the left
ventricle. The catheters were positioned until monophasic
signals were noted without suction, and then suction ( - 25
mrn Hg) was applied for no more than 3 minutes. The
monophasic action potential signals were amplified with a
direct current coupled Electronics for Medicine differential
amplifier (model PHD) and recorded on an Electronics for
Medicine VR-16 recorder with a frequency response to 2
kHz and paper speeds of 100 and 150 mm/s. The mono-
phasic action potential duration was measured at 90Ck re-
polarization during ventricular pacing cycle lengths of 600.
500 and 400 ms. During continuous pacing, the time interval
between the right ventricular apical electrogram and the
upstroke of local monophasic action potent ial recordings
was taken to represent intraventricular conduction time (Fig.
I ) . Both of these measurements represent the average of at
least three determinations obtained after 30 consecutive pac-
ing cycles.
Serum drug concentrations. Steady state trough serum
samples were obtained at the maximal tolerated dosage of
each agent and their combination. Mexiletine was assayed
using high performance liquid chromatography (5.6), and
quinidine was assayed using an enzymatic immunoassay
(EMIT) (7).
Patient follow-up. When induction of ventricular tachy-
cardia was prevented by either single or combined therapy.
patients were discharged and were evaluated monthly for 3
months. then every 3 months for the remainder of the fi rst
year and every 6 months thereafter. Each visit included a
24 hour ambulatory electrocardiographic (ECG) recording,
a 12 lead ECG. trough serum drug levels and a clinical
evaluation.
Statistical analysis. Continuous data are presented as
mean ± standard deviation. Analysis of variance and Dun-
can' s multiple range test were used to compare the effects
of mcxiletine. quinidine and their combination. The pro-
portions of patients responding to rnexiletine, quin idine and
their combination were compared by Fisher's exact test.
Results
Drug treatments. The daily dose of mexiletine and
quinidine monotherapy was 7 10 ::!: 160 and 1,080 ::!: .no
mg. respectively. The same doses were assessed during
combination therapy. Monotherapy trough serum levels were
10 ± 4 JLmollliter for quinidine and 0.7 ± 0.3 Jlg/ml for










Figure I. Measurement of conduction time (Cl')
measured from the right ventricular apical electro-
gram (RVA) to the upstroke of the right ventricular
(RV) and left ventricular (LV) monophasic action
potential (mAP). HRA = high right atrial electro-
gram.
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Figure 2. Data from the 20 patients showing the number of ex-
trastimuli (S2, S" S4) required to induce ventricular tachycardia
and the proportion of patients whose tachycardia became nonin-
ducible (Nil with each treatment. ND == not done (see text for
details); S2 == one extrastimulus: S, == two extrastimuli; S4 ==
three extrastimuli; * == significantly greater proportion of patients
responding to combination therapy relative to each monotherapy.
quinidine (8 ± 3 JLmolJliter) or mexiletine (0.6 ± 0.3 JLg/ml)
levels relative to that seen during the respective mono-
therapy. We have previously shown in vitro that combi-
nation of these two drugs in plasma does not alter the in-
dividual free fractions (8). Similarly global ejection fraction
was assessed during monotherapy and combination therapy,
and no significant changes in ejection fraction were found.
The mean ejection fraction was 35 ± 13% at baseline, 35
± 15% during quinidine monotherapy, 30 ± 15% during
mexiletine monotherapy and 30 ± 14%during combination
therapy.
Ventricular tachycardia (Fig. 2). Two patients who
responded to quinidine monotherapy and one patient who
responded to mexiletine monotherapy were not tested on
the alternative therapies. One patient did not receive mex-
iletine therapy, having already responded to combination
therapy. One additional patient was not tested with com-
bination therapy because of development of dysphoric side
effects resulting in withdrawal of consent. The proportion
of patients whose ventricular tachycardia was no longer
inducible with combination therapy (35%) was significantly
greater (X2; p < 0.01) than the proportion responding to
either mexiletine alone (5%) or quinidine alone (10%).
Other electrophysiologic effects. Mexiletine mono-
therapy had no significanteffect on electrophysiologic inter-
vals during sinus rhythm. Quinidine monotherapy signifi-
cantly prolonged the QTc interval from 450 ± 32 ms at
baseline to 507 ± 41 ms, and significantly prolonged QRS
duration from 121 ± 34 ms at baseline to 130 ± 38 ms.
The effects of combined mexiletine-quinidine therapy on
electrocardiographic intervals were not significantly differ-
ent from those of quinidine monotherapy with one excep-
tion. The QTc interval during combination therapy (480 ±
42 ms) was significantly shorter than that during quinidine
monotherapy and was not significantly different from base-
line.
Ventricular refractory periods (Table 2). The single ex-
trastimulus functional and effective refractory periods were
prolonged to a nearly identical extent by quinidine mono-
therapy and combination therapy at each of the basic drive
cycle lengths examined. Although mexiletine did not pro-
long the single extrastimulus ventricular refractory periods,
as the number of applied extrastimuli was increased, it did
prolong the effective refractory period over baseline values
(200 ± 20 ms for S4with mexiletine and 160 ± 21 ms for
S4at baseline, mean ± SD) (p < 0.05). Similarly, although
combination therapy did not prolong the singleextrastimulus
ventricular effective refractory period over that seen with
quinidine monotherapy (Fig. 3), as the number of extra-
stimuli was increased, combination therapy significantly
prolonged this period to a greater extent than did either
monotherapy. During combination therapy, the ventricular
effective refractory period of S3 measured at a pacing cycle
length of 400 ms (228 ± 40 ms) was significantly greater
than that with either monotherapy. This increase in the ven-
tricular effective refractory period of S3 with combination
treatment cannot be explained by differences in the S,S2
coupling intervals because the ventricular effective refrac-
tory period of S2 with quinidine was 258 ± 23 ms and with
combination therapy it was 255 ± 28 ms. These S,S2 cou-
pling intervals are virtually identical. Similarly, the ven-
tricular effective refractory period of S4 measured at a cycle
length of 500 ms (253 ± 26 ms) during combination treat-
ment was significantlygreater than with either monotherapy;
this increase seen with combination therapy cannot be ex-
plained by changes in the S,S2 or S2S3 coupling intervals.
The ventricular effective refractory period of S,S2 was 267
± 28 ms for quinidine and 264 ± 27 ms for combination
therapy; furthermore, that of S3 was 228 ± 39 ms for
quinidine and 233 ± 36 ms for combination therapy. There-
fore, the coupling intervals S,S2 and S2S3 with quinidine
and combination therapy were virtually identical. A similar
pattern wasobserved for the functional ventricular refractory
period. These differences between baseline and mexiletine
monotherapyand between quinidine monotherapy and com-
bination therapy were only apparent with the closely coupled
stimuli achieved by using multiple extrastimuli.
Monophasic action potentials. Eleven patients con-
sented to the additional procedures required for recording
of monophasic action potentials. Three of these patients
responded to a monotherapyand, therefore, recordings were
not obtained for the alternative monotherapy or for com-
QUINIDINEMEXILETINE COMBINATION





Table 2. Right Ventricular Effective Refractory Period (RVERP) and Right Ventricular
Functional Refractory Period (RVFRP) Determined by Single (52). Double (5,) and Triple (5-1)
Extrastimuli Techniques at Pacing Cycle Lengths of 600. 500 and 400 ms
Drive
Cycle
Length Baseline Quinidine Comhination Mexiletine
RVERP (S,) 600 252 ±- It) 2R2 ± 22 2R3 ± 27 247 ± 21
500 237 +: 20 267 ± 2R 264 ± 27 230 ± 17
400 22R ± 23 25R ±23 255 + 2R 224 ± 16
RVFRP (S,) 600 2R4 ± IR 320 ± 2R 323 ± 2R 27R ± 23
500 272 ± 20 3m ± 30 3m ± 26 267 ± 16
400 25R ± IX 2tJ2 ± 21 292 ± 21 257 ± \4
RVERP (S,) 600 IRR ± 14 246 ± 39 259 ± 39 200 ± 29
500 181 ± IX 22X ± 39 233 ± 36 198 ± 32
400 181 ± 23 216 ± 3X 22R ± 40* 176 ± IS
RYFRP(Sll 600 221 ± 21 2RS ± 30 287 ± 34 217 ± 3\
500 201 ± 21 265 ± 31 275 ± 32* 230 ± 33
400 202 + 2X 247 ± 35 257 + 34* 212 ± 16
RVERP (S.) 600 175 + 21 236 ± 34 243 ± 40 187 ± 12
500 160 ± 21 223 ±27 253 ± 26* 200 ± 20
400 N/A 207 ± 2X 240 ± 33 N/A
RYFRP (S-I) 600 IRO :+: 14 251 ± 28 259 ± 33 207 ± 25
500 185 ± 17 226 ± 27 257 ± 24* 200 ± 17
400 N/A 245 ± 48 250 ± 31 N/A
"Combination therapy significantly different from either monotherapy: significant differences of other com-
parisons are noted in the text. Results at baseline. during quinidine monotherapy, during rnexiletine monotherapy
and during comhined therapy are compared as mean ± SD. All values are in ms.
Figure 3. Relation between ventricular effective refractory period
(VERP) of the first (S2). second (5)) and third (S-I) extrastimulus
at baseline andduring treatment with mexiletine andquinidine and
their combination.
p< 0.05



















bination therapy. Five of the remaining eight patients had
recordings made during all three therapies. In three patients,
complete data could not be obtained because of procedural
complications or withdrawal of patient consent. The data
obtained from monophasic action potential recordings were
analyzed in two ways. Data from all II patients (Table 3)
were analyzed by one-way analysis of variance. Combi-
nation therapy produced a significantly greater prolongation
of conduction time from the right ventricular apex to the
left ventricular dyskinetic zone compared with that seen with
either monotherapy (Table 2). A more conservative analysis
(two-way analysis of variance) of the data obtained from
the five patients studied during all three therapies showed
the same significant difference. By the latter analysis, in
these five patients, conduction time to the left ventricular
dyskinetic zone during combination therapy was 156 ± 44
ms, during quinidine monotherapy it was 130 ± 30 ms and
during mexiletine monotherapy it was 94 ± 13 ms (p <
0.02).
Patient follow-up. Six patients were discharged while
receiving combination therapy. During a mean follow-up
period of 14 ± 8 months, one patient had a nonarrhythmic
cardiac death. All other patients continue receiving therapy
and are free of episodes of ventricular tachycardia (as as-
sessed by serial 24 hour ambulatory ECG monitoring). Three
patients who responded to single therapy are well and ar-
rhythmia-free during follow-up. Of the 10 patients not re-
sponding to mexiletine, quinidine or the combination, ef-
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Table 3. Electrophysiologic Measurements
Drive
Cycle
Variable Length Baseline Quinidine Combination Mexiletine
CT to LV 600 N/A 108 ± 28 150 ± 47* 106 ± 18
500 N/A 127 ± 36 144 ± 43* 96 ± 13
400 N/A 118 ± 30 152 ± 44* 106 ± 19
RV mAPD 600 N/A 296 ± 23 305 ± 40 271 ± 39
500 N/A 285 ± 30 273 ± 18 264 ± 21
400 N/A 260 ± 20 256 ± 15 249 ± 24
LV mAPD 600 N/A 291 ± 33 269 ± 43 275 ± 39
500 N/A 267 ± 37 249 ± 35 257 ± 2S
400 N/A 271 ± 39 232 ± 15 224 ± 34
QRS duration 121 ± 34 130 ± 38 128 ± 33 129 ± 43
QTc interval 450 ± 32 507 ± 41 480 ± 42 470 ± 38
RR interval 782 ± 137 717 ± 90 688 ± fl,7 705 ± 110
*Combination therapy significantlydifferent from either monotherapy; significant differences of other com-
parisons are indicated in the text. Intraventricular conduction time (CT to LV). monophasic action potential
duration at 90% repolarization from the right ventricle (RV mAPD) and left ventricular dyskinetic zone (LV
mAPD) and standard surface electrocardiographic intervalscomparedat baseline. during quinidine monotherapy.
during mexiletine monotherapy and during combined therapy. All values arc in ms.
fective antiarrhythmic therapy was found for only I patient
(who responded to sotalol). Of the remaining nine patients,
one was discharged while receiving disopyramide (the best
partially effective agent) and the other eight were given
empiric amiodarone treatment.
Discussion
Enhanced antiarrhythmic efficacy has been reported (1,3)
during combination treatment with mexiletine and quinidine
in patients with malignant ventricular arrhythmias. In a re-
perfusion injury model (9), we have shown that mexiletine
and quinidine produce synergistic prolongation of ventric-
ular refractoriness and conduction time in the infarct zone
in a conscious dog model, and that these electrophysiologic
changes were paralleled by enhanced antiarrhythmic effi-
cacy. The present study confirms that synergistic antiar-
rhythmic and electrophysiologic changes occur with this
drug combination in humans. The changes in ventricular
conduction time and refractoriness observed in these studies
are in keeping with the hypothesis that the synergistic effects
of this combination therapy are related to an interaction
affecting sodium conductance.
Synergistic effects of quinidine and mexiIetine. Hon-
deghem and Katzung (10), using a computer model of the
sodium channel, predicted that the combination of lidocaine
and quinidine would synergistically affect extrastimulus
electrophysiology. The hypothesis developed to explain these
synergistic actions was based on antiarrhythmic drugs hav-
ing distinctive, state-dependent dissociation and association
rate constants to the sodium channel. Quinidine binds to the
activated state of the sodium channel, generating a modu-
lated activated state. The binding of quinidine to the inac-
tivated state of the sodium channel is minimal but, if bound,
recovery from inactivation is markedly prolonged (II). In
contrast, lidocaine and mexiletine bind preferentially to the
inactivated state of the sodium channel generating a mod-
ulated inactivated state (12,13). Once in the "modulated"
inactivated state, quinidine can express its property to de-
layed recovery from inactivation (10). Recovery from in-
acti vation appears to be an important determinant of ven-
tricular refractoriness (10). Although this is an attractive
hypothesis, it has not been rigorously tested. An alternative
hypothesis is that when two drugs are combined, the total
number of sodium channel blocking molecules is greater
than when the drugs are given as monotherapy at equal
dosages.
Role of sodium channel gating in ventricular refrac-
toriness. In the present study, the synergistic effects of
combination therapy on ventricular refractoriness were most
evident with the application of closely coupled extrastimuli
at rapid pacing rates. The increase in the ventricular effective
refractory period of S4 seen with combination therapy rel-
ative to quinidine mono therapy cannot be explained by dif-
ferences in the coupling intervals of SI S2 or S2S" These
coupling intervals were virtually identical. Nevertheless, the
mean ventricular effective refractory period of S4 during
combination therapy is 30 ms greater than that seen during
treatment with quinidine alone. These observations suggest
that combination therapy produces a frequency-dependent
prolongation in ventricular refractoriness. The cellular
mechanism of this frequency-dependent alteration in re-
fractoriness is uncertain. Ventricular effective refractoriness
is determined by a number of factors, including action po-





tential duration and the time course of recovery from in-
activationof the sodium channel. In this study, we observed
no difference in action potential duration when comparing
quinidine monotherapy and combination therapy, However,
we cannot exclude differences in action potential duration
of V~ and VJ' Altematively, there is experimental support
for the possibility that the recovery kinetics of the sodium
channel can alter refractoriness. In the study by Hondeghem
and Katzung (14) comparing the maximal rate of rise of the
action potential of extrasystoles at various coupling inter-
vals, combination therapy with lidocaine and quinidine
produced a supra-additive depression of the maximal rate
of rise (Vmax) of the action potential of closely coupled
extrasystoles. This observation provides a link between drug-
related changes in the kinetics of sodium channel gating and
the changes in refractoriness of closely coupled extrastimuli
observed in the present study.
Pharmacodynamic interactions. The steady state serum
concentrations of mexiletine and quinidine monotherapy were
not altered by combination therapy; therefore, there is no
evidence for a pharmacokinetic interaction, This observation
is supported by in vitro observations (15) of synergistic
electrophysiologic effects of combination therapy in a set-
ting where pharmacokinetic interactions could not be op-
erative, The mexiletine-quinidine interaction is, therefore,
likely to be pharmacodynamic.
Limitations of study. There are several limitations of
this study, Conduction time was measured as the time elapsed
from the right ventricular electrogram to the upstroke of the
local monophasic action potentials. Change in conduction
time may reflect true changes in conduction velocity, but
may also be effected by change in the route of propagation
or change in latency, This may be particularly relevant for
measurements made from the infarct zone. Monophasic ac-
tion potential catheters have been used to measure local
repolarization time in normal and infarct zones (16). Al-
though these measurements have been validated against rni-
croelectrode recordings of action potential duration in nor-
mal myocardium (17), this comparison has not been made
in infarcted tissue, The monophasic action potential mea-
surements made from the left ventricle were of lower am-
plitude than those recorded from the right ventricle and,
therefore, these repolarization measurements may be less
accurate,
Another potentia/limitation (~f this study is that, although
we attempted to place the left ventricular monophasicaction
potential catheter into a zone of abnormal wall motion, we
have no confirmation of the exact placement of this catheter
in relation to infarct or border zones. Although the catheter
was radiologically guided during the three individual studies
(mexiletine, quinidine and their combination) to approxi-
mate the same position for each study, it is unlikely that
monophasic action potential recordings were obtained in
exactly the same positions in all three studies. These pro-
cedurallimitations exist for all similar clinical investigations
employing these catheter techniques.
The number of patients participating in this study was
small. Therefore, it is possible that additional significant
electrophysiologicdifferences exist, but were not identified.
Enrollment in this study was terminated on ethical grounds
secondary to an unacceptable complication rate of arterial
catheterization with the monophasic action potential cath-
eter. These complications affected four patients and in-
cluded a transient cerebral ischemic attack, possible myo-
cardial perforation, iliac artery embolic occlusion and a
femoral artery false aneurysm. Although no long-term se-
quelae occurred, two surgical procedures were required to
correct these complications.
Conclusions. Combination therapy with mexiletine and
quinidine suppressed the inducibility of ventricular tachy-
cardia more than did either monotherapy. This enhanced
antiarrhythmic effect is paralleled by prolongation of ven-
tricular refractoriness and the conduction time to a zone of
the left ventricle with a segmental wall motion abnormality,
We hypothesize that the observed electrophysiologic dif-
ferences between monotherapy with each drug and com-
bination therapy are related to the enhanced antiarrhythmic
activity of this combination.
We thank Gregory Douglas for help in preparing the manuscript.
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